IOL Chemicals and Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
IOL Chemicals and Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 27.5% bzw. 11.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 27.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.3% betragen.
Wichtige Informationen
27.5%
Wachstumsrate der Gewinne
27.5%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 18.3% |
| Wachstumsrate der Einnahmen | 11.1% |
| Zukünftige Eigenkapitalrendite | 11.3% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 19 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
A Piece Of The Puzzle Missing From IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Share Price
Sep 11
Is There An Opportunity With IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) 34% Undervaluation?
Jun 12Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Aug 30IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Has A Pretty Healthy Balance Sheet
May 18IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Will Pay A Dividend Of ₹4.00
Feb 10Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Jun 07Calculating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
May 07Do IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Warrant Your Attention?
May 04Is IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP) An Attractive Dividend Stock?
Mar 13Is IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Using Too Much Debt?
Feb 23Should You Rely On IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) Earnings Growth?
Feb 08IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 27How Does IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Salary Compare to Peers?
Jan 15Estimating The Intrinsic Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Jan 02
Shareholders of IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Must Be Delighted With Their 869% Total Return
Dec 21Is Now The Time To Put IOL Chemicals and Pharmaceuticals (NSE:IOLCP) On Your Watchlist?
Dec 09These 4 Measures Indicate That IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Is Using Debt Reasonably Well
Nov 24IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Could Be A Buy For Its Upcoming Dividend
Nov 12Is There More To The Story Than IOL Chemicals and Pharmaceuticals's (NSE:IOLCP) Earnings Growth?
Nov 09Will Weakness in IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Stock Prove Temporary Given Strong Fundamentals?
Oct 27Here's What We Think About IOL Chemicals and Pharmaceuticals' (NSE:IOLCP) CEO Pay
Oct 09Calculating The Fair Value Of IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
Sep 18Here's Why I Think IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Might Deserve Your Attention Today
Sep 03Cautious Investors Not Rewarding IOL Chemicals and Pharmaceuticals Limited's (NSE:IOLCP) Performance Completely
Aug 16IOL Chemicals and Pharmaceuticals (NSE:IOLCP) Seems To Use Debt Rather Sparingly
Jul 27Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2027 | 27,438 | 2,193 | N/A | 2,953 | 1 |
| 3/31/2026 | 26,118 | 2,257 | 783 | 2,727 | 2 |
| 3/31/2025 | 24,071 | 1,823 | 297 | 1,942 | 2 |
| 9/30/2024 | 20,521 | 998 | -1,586 | 1,273 | N/A |
| 6/30/2024 | 20,720 | 1,185 | N/A | N/A | N/A |
| 3/31/2024 | 21,328 | 1,344 | 159 | 2,901 | N/A |
| 12/31/2023 | 22,161 | 1,716 | N/A | N/A | N/A |
| 9/30/2023 | 22,192 | 1,723 | 62 | 2,582 | N/A |
| 6/30/2023 | 22,153 | 1,503 | N/A | N/A | N/A |
| 3/31/2023 | 22,171 | 1,391 | -895 | 1,223 | N/A |
| 12/31/2022 | 22,024 | 1,041 | N/A | N/A | N/A |
| 9/30/2022 | 22,341 | 1,204 | -538 | 824 | N/A |
| 6/30/2022 | 22,305 | 1,353 | N/A | N/A | N/A |
| 3/31/2022 | 21,840 | 1,677 | -602 | 931 | N/A |
| 12/31/2021 | 20,719 | 2,132 | N/A | N/A | N/A |
| 9/30/2021 | 20,298 | 2,879 | 703 | 2,228 | N/A |
| 6/30/2021 | 20,254 | 3,840 | N/A | N/A | N/A |
| 3/31/2021 | 19,670 | 4,446 | 2,716 | 3,798 | N/A |
| 12/31/2020 | 19,481 | 4,596 | N/A | N/A | N/A |
| 9/30/2020 | 19,463 | 4,428 | 2,902 | 3,779 | N/A |
| 6/30/2020 | 18,618 | 4,035 | N/A | N/A | N/A |
| 3/31/2020 | 18,945 | 3,613 | 3,905 | 4,708 | N/A |
| 12/31/2019 | 18,753 | 3,727 | N/A | N/A | N/A |
| 9/30/2019 | 18,423 | 3,569 | N/A | N/A | N/A |
| 6/30/2019 | 18,163 | 3,076 | N/A | N/A | N/A |
| 3/31/2019 | 16,853 | 2,367 | 2,126 | 2,732 | N/A |
| 12/31/2018 | 15,506 | 1,465 | N/A | N/A | N/A |
| 9/30/2018 | 13,350 | 731 | N/A | N/A | N/A |
| 6/30/2018 | 11,298 | 391 | N/A | N/A | N/A |
| 3/31/2018 | 9,833 | 277 | N/A | 1,197 | N/A |
| 12/31/2017 | 8,891 | 178 | N/A | N/A | N/A |
| 9/30/2017 | 8,094 | 100 | N/A | N/A | N/A |
| 6/30/2017 | 8,265 | 65 | N/A | N/A | N/A |
| 3/31/2017 | 7,107 | 47 | N/A | 833 | N/A |
| 12/31/2016 | 6,595 | 39 | N/A | N/A | N/A |
| 9/30/2016 | 6,197 | -74 | N/A | N/A | N/A |
| 6/30/2016 | 6,055 | -214 | N/A | N/A | N/A |
| 3/31/2016 | 5,804 | -400 | N/A | 177 | N/A |
| 12/31/2015 | 5,131 | -692 | N/A | N/A | N/A |
| 9/30/2015 | 4,377 | -890 | N/A | N/A | N/A |
| 6/30/2015 | 4,008 | -858 | N/A | N/A | N/A |
| 3/31/2015 | 3,847 | -667 | N/A | -470 | N/A |
| 12/31/2014 | 4,405 | -378 | N/A | N/A | N/A |
| 9/30/2014 | 5,115 | -71 | N/A | N/A | N/A |
| 6/30/2014 | 5,452 | 37 | N/A | N/A | N/A |
| 3/31/2014 | 5,635 | 33 | N/A | 784 | N/A |
| 12/31/2013 | 5,684 | 26 | N/A | N/A | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IOLCPDas prognostizierte Gewinnwachstum (27.5% pro Jahr) liegt über der Sparquote (6.7%).
Ertrag vs. Markt: IOLCPDie Erträge des Unternehmens (27.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (18% pro Jahr).
Hohe Wachstumserträge: IOLCPEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: IOLCPDie Einnahmen des Unternehmens (11.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (10.5% pro Jahr).
Hohe Wachstumseinnahmen: IOLCPDie Einnahmen des Unternehmens (11.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: IOLCPDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.3%).